|
Synonyms: compound PPA-044 [WO2022263604] | CT-7439 | CT7439
Compound class:
Synthetic organic
Comment: Baleraciclideg is the INN for a cyclin-dependent kinase degrader that was included in WHO INN Proposed List 135 (July 2026). The structure is claimed in Carrick Therapeutics' patent WO2022263604A1, as a CDK12/13 inhibitor and cyclin K molecular glue class degrader [1]. The inhibitor is proposed to simultaneously occupy kinase domain of CDK12 and engage the hydrophobic pocket of the DDB1 E3 ligase to promote cyclin K degradation. Carrick Therapeutics have a declared lead compound called CT7439 with this functionality in their development pipeline [2]. CT7439 is an orally bioavailable compound.
Targeting various CDKs is an established anti-tumour strategy. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||